Gilead and Kite Announce Layoffs, Closing Seattle and Philadelphia Facilities Amid Strategic Reorientation
Gilead Sciences recently announced layoffs as part of a strategic shift aimed at realigning resources. The layoffs involve 72 employees at its Seattle facility, which will shut down by January 17, 2024, following a focus on research and clinical development[1][2]. In addition to the Seattle closure, Kite Pharma, a subsidiary of Gilead, is planning to close its Philadelphia facility by mid-2024. These moves are part of a broader reorientation strategy, involving previous workforce reductions of around 7% at Kite, which are intended to position the company for future growth, including the launch of new products by 2030[1].
References
Explore Further
What specific criteria were used by Gilead and Kite to determine the closure of the Seattle and Philadelphia facilities?
How do Gilead Sciences and Kite Pharma plan to utilize the resources saved from these layoffs and facility closures?
What alternative opportunities are being provided to the employees affected by the layoffs at Gilead's Seattle and Kite's Philadelphia locations?
How does Gilead Sciences plan to address the challenges it faces with its cell therapy products?
What are the anticipated new products that Gilead aims to launch by 2030, and how will these shape the company's future strategy?